Halozyme Therapeutics Hits New 52-Week High of $104.73, Up 100.59%

Halozyme Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 104.73 on August 10, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 7,273 million. Over the past year, Halozyme has demonstrated impressive growth, with a performance increase of 100.59%, significantly outpacing the S&P 500's 21.34% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 11.00, indicating a favorable valuation compared to its industry peers. Additionally, Halozyme boasts an extraordinary return on equity of 1,371.85%, reflecting its effective management and profitability. Despite a debt-to-equity ratio of 41.20, the company maintains a solid financial position, with no dividend yield reported. The stock's previous 52-week low was recorded at USD 61.23, highlighting the substantial upward movement in its price. This recent high marks a notable achievement for Halozyme Therapeutics, Inc. in a competitive market landscape.